Climb Bio (CLYM) Cash from Investing Activities (2020 - 2026)

Climb Bio (CLYM) has 7 years of Cash from Investing Activities data on file, last reported at -$13.0 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 69.7% year-over-year to -$13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.6 million (up 118.37% YoY) and the FY2025 annual result came in at $2.8 million, up 102.34% from the prior year.
• Cash from Investing Activities eased to -$13.0 million in Q1 2026, from $25.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $36.7 million in Q4 2023 to a low of -$71.8 million in Q3 2024.
• A 5-year average of -$1.6 million and a median of $5.8 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 277.34% — and 2024, when it tumbled 502.44%.
• Tracing CLYM's Cash from Investing Activities over 5 years: stood at $14.3 million in 2022, then jumped by 157.37% to $36.7 million in 2023, then sank by 245.34% to -$53.4 million in 2024, then soared by 147.82% to $25.5 million in 2025, then tumbled by 150.73% to -$13.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$13.0 million (Q1 2026), $25.5 million (Q4 2025), and $15.3 million (Q3 2025), per Business Quant data.